Drug
Telmisartan (Kinzal/Pritor, BAY68-9291)
Telmisartan (Kinzal/Pritor, BAY68-9291) is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completed
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
NCT01211171
completed
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
NCT00927537
completed
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia
NCT01217879
completed
Assessment of Compliance With Antihypertensive Telmisartan Therapy
NCT00470886
completed
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
NCT01071681
Clinical Trials (5)
Showing 5 of 5 trials
NCT01211171
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-I Treatment Due to couGH in Poland
NCT00927537
Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
NCT01217879
COugh Among Hypertensive Patients Treated With Telmisartan, Who Had to Stop previoUs ACE-i Treatment Due to couGH in Slovakia
NCT00470886
Assessment of Compliance With Antihypertensive Telmisartan Therapy
NCT01071681
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5